Investor Presentation Full Year 2021
48
Investor presentation Full year 2021
Novo NordiskⓇ
GLP-1 effect dependent on blood glucose level
GLP-1 mechanism of action when blood
sugar levels increase
Creates sense of satiety in the brain
Brain
Diabetes
CVD
Reduces
glucagon
secretion in
the liver
GLP-1
Liver
Slows gastric
emptying in
the gut
Obesity
Gut
Pancreas
Increases insulin secretion in the pancreas
NASH
CKD
Brain
disorders
Semaglutide holds a plethora of
therapeutic opportunities¹
FORTE-Semaglutide 2.0 mg
Semaglutide s.c. ~961 patients, T2D
FOCUS - Diabetic retinopathy outcomes trial
Semaglutide s.c; ~1,500 patients, T2D ≥10 years
SOUL - Cardiovascular outcomes trial
Oral semaglutide; ~9,600 patients, T2D, established CVD
or CKD
SELECT - Cardiovascular outcomes trial
Semaglutide 2.4 mg, ~17,500 patients with obesity
and without diabetes, event driven
Semaglutide in NASH
Semaglutide s.c.; phase 2 trials
FLOW - Chronic kidney disease outcomes trial
Semaglutide 1.0 mg; ~3,200 patients, T2D, moderate
to severe CKD
Alzheimer's Disease
Oral Semaglutide 14 mg; ~ 3,700 patients with early
Alzheimer's disease
1 List is not exhaustive
Sc: Subcutaneous; T2D: Type 2 diabetes; CVD: Cardiovascular disease; CKD: Chronic kidney disease; NASH: Non-alcoholic steatohepatitisView entire presentation